Connection

Chong Yu to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications Chong Yu has written about Antineoplastic Agents.
Chong Yu
Connection Strength
0.856
Antineoplastic Agents
  1. Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go? Eur J Cancer. 2018 11; 103:32-40.
    View in: PubMed
    Score: 0.237
  2. Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan. Cancer Med. 2017 Jul; 6(7):1563-1572.
    View in: PubMed
    Score: 0.218
  3. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. Oncologist. 2017 09; 22(9):1075-1083.
    View in: PubMed
    Score: 0.217
  4. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs. J Thorac Oncol. 2019 03; 14(3):513-526.
    View in: PubMed
    Score: 0.060
  5. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. Lancet Respir Med. 2018 02; 6(2):107-116.
    View in: PubMed
    Score: 0.056
  6. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017 03 04; 389(10072):917-929.
    View in: PubMed
    Score: 0.053
  7. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study. Lung Cancer. 2017 02; 104:58-64.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.